US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...
In 2025, DriveItAway continued its transition from early-stage innovation to national execution, anchored by strengthened governance, expanded market presence, and growing validation of its flexible ...
Department of Chemical Technology and Environmental Analysis, Faculty of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, 31-155 Cracow, Poland South Australian ...
Molecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, IA, United States C3 Glomerulopathy (C3G) is a renal disease mediated primarily by dysregulation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback